GENEVA, Sept. 22, 2015 /PRNewswire/ -- Selexis SA, a serial innovation company with proven technologies for characterized mammalian Research Cell Banks (RCBs) used for drug discovery to commercial manufacturing, announced today the signing of a Service Agreement with Swedish Orphan Biovitrum AB (Sobi), a leading biopharmaceutical company focused developing therapies and services for people living with rare diseases.
Under the agreement, Selexis will use the SURE CHO-Mplus Libraries to address issues with difficult-to-express proteins.
"With the application of our new technologies, we are pleased to help Sobi reach their protein expression goal," said Marco Bocci, PhD, vice president of business development and licensing of Selexis. "Our recent efforts in deciphering our CHO-M cell line is making a footprint in helping biopharmaceutical companies with advancing difficult-to-express proteins into the clinic and ultimately the patient."
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies for biologic drug discovery and mammalian Research Cell Banks for scale-up to manufacturing of recombinant therapeutic proteins. With the Company's SUREtechnology Platform™ biopharmaceutical companies can significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for the production of monoclonal antibodies (MAbs) and other recombinant proteins including difficult-to-express proteins such as plasma proteins, GPCRs and non-natural proteins such as fusion proteins. Selexis generated cell lines are being used in a variety of programs from drug discovery to a commercial product.
FOR MORE INFORMATION
Media Inquires for Selexis
Head, Corporate Communications
Tel. +1 602 953 1717
Company Inquiries for Selexis
Marco Bocci, PhD, DPharm
Vice President, European Licensing and Business Development
Tel. +41 22 308 93 26
SOURCE Selexis SA